HC Wainwright Issues Positive Outlook for Nuvalent Earnings

Nuvalent, Inc. (NASDAQ:NUVL) – Analysts at HC Wainwright boosted their Q1 2026 earnings per share estimates for Nuvalent in a research report issued on Monday, March 2nd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($1.26) per share for the quarter, up from their previous forecast of ($1.53). HC Wainwright currently has a “Buy” rating and a $155.00 target price on the stock. The consensus estimate for Nuvalent’s current full-year earnings is ($3.86) per share. HC Wainwright also issued estimates for Nuvalent’s Q2 2026 earnings at ($1.21) EPS, Q3 2026 earnings at ($1.16) EPS, Q4 2026 earnings at ($0.94) EPS, FY2026 earnings at ($4.57) EPS, FY2027 earnings at ($2.06) EPS, FY2028 earnings at $2.11 EPS and FY2030 earnings at $2.59 EPS.

A number of other equities research analysts have also issued reports on NUVL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvalent in a report on Thursday, January 22nd. Stifel Nicolaus lifted their price target on shares of Nuvalent from $115.00 to $135.00 and gave the company a “buy” rating in a report on Monday, November 17th. Cantor Fitzgerald increased their price objective on shares of Nuvalent from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Friday, February 27th. UBS Group restated a “buy” rating on shares of Nuvalent in a research report on Wednesday, December 17th. Finally, The Goldman Sachs Group boosted their target price on Nuvalent from $120.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Fifteen analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $138.67.

Nuvalent Trading Up 2.4%

NASDAQ:NUVL opened at $102.67 on Thursday. The stock has a 50-day moving average price of $103.25 and a 200 day moving average price of $95.69. Nuvalent has a 12-month low of $55.53 and a 12-month high of $113.01. The stock has a market capitalization of $7.47 billion, a P/E ratio of -17.55 and a beta of 1.32.

Insider Buying and Selling at Nuvalent

In other news, insider Henry E. Pelish sold 2,664 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $97.17, for a total transaction of $258,860.88. Following the transaction, the insider owned 65,888 shares of the company’s stock, valued at approximately $6,402,336.96. The trade was a 3.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Deborah Ann Miller sold 14,300 shares of the firm’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $110.16, for a total value of $1,575,288.00. Following the completion of the sale, the insider owned 59,634 shares of the company’s stock, valued at approximately $6,569,281.44. This represents a 19.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 76,463 shares of company stock valued at $7,722,489. Corporate insiders own 10.20% of the company’s stock.

Institutional Investors Weigh In On Nuvalent

Hedge funds and other institutional investors have recently made changes to their positions in the company. Seven Fleet Capital Management LP bought a new stake in shares of Nuvalent in the 4th quarter worth about $1,268,000. T. Rowe Price Investment Management Inc. grew its holdings in Nuvalent by 29.3% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,319,963 shares of the company’s stock valued at $132,776,000 after purchasing an additional 298,727 shares during the last quarter. Invesco Ltd. raised its position in Nuvalent by 1,201.4% in the 4th quarter. Invesco Ltd. now owns 439,300 shares of the company’s stock worth $44,189,000 after purchasing an additional 405,543 shares during the period. XTX Topco Ltd purchased a new stake in Nuvalent in the 4th quarter worth about $1,559,000. Finally, Ikarian Capital LLC bought a new stake in Nuvalent in the fourth quarter worth about $5,995,000. Hedge funds and other institutional investors own 97.26% of the company’s stock.

Key Headlines Impacting Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: HC Wainwright raised Q1–Q4 2026 and FY2026 EPS estimates (Q1: from ($1.53) to ($1.26); Q2: ($1.48) to ($1.21); Q3: ($1.43) to ($1.16); Q4: ($1.19) to ($0.94); FY2026: ($5.62) to ($4.57)) — the firm is modeling smaller near-term losses, which supports a more constructive valuation outlook. Read More.
• Positive Sentiment: HC Wainwright increased multi‑year earnings power: FY2028 was raised to $2.11 (from $1.75) and FY2030 is modeled at $2.59 — this improves the long‑term pathway to profitability that investors prize for growth biotech stocks. Read More.
• Positive Sentiment: The analyst maintained a Buy rating and a $155 price target — a clear signal of continued analyst conviction that likely supports buying interest. Read More.
• Neutral Sentiment: Corporate/market context: Nuvalent remains a loss‑making biotech by GAAP (negative P/E), with a market cap around $7.5B and shares trading nearer recent highs — volatility and binary clinical/regulatory outcomes remain key risk drivers beyond model revisions. Read More.
• Negative Sentiment: HC Wainwright cut FY2027 and FY2029 estimates (FY2027 from ($1.69) to ($2.06); FY2029 from $6.77 to $6.52) — some intermediate-year assumptions were weakened, which could temper upside if management or pipeline progress lags these timelines. Read More.
• Negative Sentiment: Despite the upgrades, HC Wainwright’s FY2026 loss projection (-$4.57) remains more negative than the consensus (-$3.86) — differing views on near-term execution or commercial ramp risks could keep volatility elevated. Read More.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.